Recursion Pharmaceuticals, Inc. (RXRX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Recursion Pharmaceuticals reported revenue of $74.7M, up 26.9% from $58.8M the year before. Net income was -$644.8M (a -863.4% net margin), or -$1.44 per diluted share. Gross margin was 5.0% and operating margin was -867.9%. Operating activities generated -$371.8M of cash, leaving -$378.3M of free cash flow. At fiscal year end, Recursion Pharmaceuticals held $1.47B in total assets against $343.3M in total liabilities, including $743.3M of cash and equivalents.
Open the full interactive Recursion Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Recursion Pharmaceuticals Key Stats
| Share Price | $3.84 |
|---|---|
| Market Cap | $2.04B |
| Revenue YoY Growth | +26.9% |
| 52-Week Range | $2.84 – $6.79 |
| Shares Outstanding | 532.5 million (basic, 2026 Q2) |
Recursion Pharmaceuticals Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $10.2M | $39.8M | $44.6M | $58.8M | $74.7M |
| Cost of Goods Sold | — | $48.3M | $42.6M | $45.2M | $71.0M |
| Gross Profit | — | -$8.4M | $2.0M | $13.6M | $3.7M |
| Operating Income | -$182.8M | -$245.7M | -$350.1M | -$479.0M | -$648.1M |
| Pre-Tax Income | -$186.5M | -$239.5M | -$332.1M | -$464.8M | -$644.9M |
| Income Tax | $0 | $0 | -$4.1M | -$1.1M | -$136,000 |
| Net Income | -$186.5M | -$239.5M | -$328.1M | -$463.7M | -$644.8M |
| Diluted EPS | -$1.49 | -$1.36 | -$1.58 | -$1.69 | -$1.44 |
Recursion Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $5.2M | $35.5M | $6.5M | $7.7M |
| Net Income | -$162.3M | -$108.1M | -$117.5M | -$131.0M |
| Diluted EPS | -$0.36 | -$0.24 | -$0.22 | -$0.25 |
Recursion Pharmaceuticals Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $285.1M | $549.9M | $391.6M | $594.4M | $743.3M |
| Current Assets | $534.7M | $569.8M | $438.1M | $714.3M | $812.8M |
| Total Assets | $610.3M | $701.3M | $653.7M | $1.45B | $1.47B |
| Current Liabilities | $46.7M | $100.3M | $93.2M | $187.5M | $147.7M |
| Total Long-Term Debt | $723,000 | $633,000 | $1.1M | $27.4M | $18.7M |
| Total Liabilities | $67.4M | $215.5M | $190.3M | $413.8M | $343.3M |
| Shareholders' Equity | $542.9M | $485.8M | $463.4M | $1.03B | $1.13B |
Recursion Pharmaceuticals Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$158.6M | -$83.5M | -$287.8M | -$359.2M | -$371.8M |
| Cash From Investing | -$271.7M | $193.2M | -$10.2M | $260.1M | -$16.9M |
| Cash From Financing | $458.5M | $154.3M | $140.1M | $304.1M | $521.5M |
| Free Cash Flow | -$198.4M | -$120.6M | -$299.7M | -$372.9M | -$378.3M |
Figures from Recursion Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Recursion Pharmaceuticals financials page for every line item.
Recursion Pharmaceuticals Company Profile
| Ticker | RXRX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Salt Lake City, Utah |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001601830 |
Frequently Asked Questions
What was Recursion Pharmaceuticals' revenue in fiscal 2025?
Recursion Pharmaceuticals (RXRX) reported revenue of $74.7M for fiscal 2025.
What is Recursion Pharmaceuticals' annual revenue history?
Recursion Pharmaceuticals' annual revenue by fiscal year: 2021: $10.2M; 2022: $39.8M; 2023: $44.6M; 2024: $58.8M; 2025: $74.7M.
What was Recursion Pharmaceuticals' net income in fiscal 2025?
Recursion Pharmaceuticals reported net income of -$644.8M for fiscal 2025.
What was Recursion Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Recursion Pharmaceuticals' diluted EPS was -$1.44 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Recursion Pharmaceuticals generate in fiscal 2025?
Recursion Pharmaceuticals generated -$378.3M of free cash flow in fiscal 2025.
What was Recursion Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Recursion Pharmaceuticals reported revenue of $7.7M.
How much debt does Recursion Pharmaceuticals have?
Recursion Pharmaceuticals reported $18.7M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Recursion Pharmaceuticals are outstanding?
Recursion Pharmaceuticals reported a weighted average of 532.5 million basic shares outstanding in 2026 Q2.
What is Recursion Pharmaceuticals' market cap?
Based on its latest closing price, Recursion Pharmaceuticals (RXRX) has a market capitalization of about $2.04B.
When does Recursion Pharmaceuticals' fiscal year end?
Recursion Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Recursion Pharmaceuticals headquartered?
Recursion Pharmaceuticals lists its business address in Salt Lake City, Utah in its SEC filings.
Recursion Pharmaceuticals Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →